Loading
Latest filing published 18 Sept 2025 for Y-mAbs Therapeutics, Inc., €1.8M.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Thomas Gad, listed as senior executive, appears in our data through filings on Y-mAbs Therapeutics, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 9 April 2019 to 16 September 2025, the count stands at 159 filings.
The open-market record consists of 124 sales worth €41.3M, with no purchase. The rest of the record consists of 3 share grants and 23 option exercises. Since January 2025: no purchases and 1 sale on the market.
The record was last updated on 18 September 2025 with a transaction (€435k) in Y-mAbs Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 38 declarations